RE:Zenith webcastI can't get the Zenith update out of my mind.
In point 1 in my last post I said Don referred to early data sets on zen3694 in a couple of months. This makes me very hopeful however the enzalutamide trial has only started dosing. Having been around for a very long time I started thinking about Don's "couple of months" statement and Don's couple of months could well mean 6 months or more. I've become very suspicious of Don's time lines from past experience. I hope that it actually is a couple (meaning 2) of months!
On the 7th point of my post I went back to look at the pdf of the webcast. On page 12 Don listed the Principlal Investigators (of which there are 8 highly qualified and relevant specialists) and 2 really stand out.
1. Eric Small, M.D. Chief, Department of Medicine.
- University of California, San Francisco.
- Developed abiraterone - #2 CRCP drug - owned by J & J.
2. Howard Scher, M.D. Chief, Genitourinary Oncology.
- Memorial Sloane Kettering Cancer Center.
- Developed enzalutamide - #1 CRPC drug, now owned by Pfizer.
- Developing ARN-509 for J & J.
So it strikes me to be of significant value to have experts that were directly involved in the development in the 2 standard of care drugs for CRPC. And, it is well known that these drugs lose their effectiveness after a period of time and that zen3694 working on BRD4 has the potential to make these drugs become effective after resistance and the zen3694 may have a positive impact on CRPC on it's own. We should know something about that from phase 1 soon (perhaps that is the 2 months Don referred to).
From my perspective I think Zenith approaches must be of significant interest to these scientists.
So perhaps scientists at J & J and Pfizer may start to keep an early eye on this compound and other Zenith compounds, science and IP.
The other exciting aspect is the potential for zen3694 to work in synergistic action with many indications including melanoma, breast cancers, etc as illustrated on page 26.
I urge everyone to download the presentation and review it from time to time.
GLTA
Toinv